A new study published in Neuromodulation1 demonstrates that automatic, daily remote monitoring of spinal cord stimulation (SCS) devices enables the first real-time visibility into post-implant therapy ...
The U.S. Food and Drug Administration (FDA) approved Abbott (ABT)'s Eterna™ spinal cord stimulation (SCS) system for the treatment of chronic pain This neuromodulation device provides an optimized ...
Nevro Announces U.S. Launch of Senza® Omnia(TM) Spinal Cord Stimulation System to Treat Chronic Pain
REDWOOD CITY, Calif., Nov. 5, 2019 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that provides innovative, evidence-based solutions for the treatment of chronic pain, today ...
CARLSBAD, Calif.--(BUSINESS WIRE)--Nalu Medical, Inc (“Nalu”) is a Carlsbad, California-based company that has successfully miniaturized neurostimulation implants for the management of chronic ...
POMPANO BEACH, Fla.--(BUSINESS WIRE)--Stimwave Technologies, the leading innovator of wireless medical device bioelectronic technology, today announced pending publication and completion of long-term ...
How Medtronic spinal cord stimulation therapy helped one woman reclaim her life. For more than a decade, Lynnette lived in the shadow of debilitating pain. What began as persistent discomfort in her ...
Nevro Corp. NVRO recently announced that it has received CE mark approval for the Senza Omnia Spinal Cord Stimulation (SCS) system. This is a next-generation SCS system, which has been created and ...
Abbott developed Eterna based on extensive studies with patients, physicians and caregivers to understand the unmet needs of people living with chronic pain. The studies found that people wanted a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback